Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease
Practice Guideline, November 2021
Read Published ArticleThis practice guideline update includes conclusions and recommendations that address the efficacy and adverse effects of levodopa, dopamine agonists, and MAO-B inhibitors for treating motor symptoms of early Parkinson disease.
Endorsed by the Parkinson's Foundation.
Reaffirmed on February 8, 2025.
Clinician Tools and Materials
Full-length Version
Download a PDF of the full guideline product, including full details of the methodology and data analysis
Clinician Summary
Download a PDF summary of this guideline product
Pocket Guideline Clinician Summary
Access a digital interactive summary of the recommendations and other key information from the guideline
好色先生al Materials
Other resources related to this guideline
Patient Tools and Materials
Patient Summary
Read a summary of the key messages of this guideline product for patients and care partners.